Genalyte
PrivateLast Round
Series C
Extension
Apr 21, 2023
Est. Valuation
$302.19M
Total Funding Raised
$74.8M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Genalyte operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series C Extension round in April 2023.
Genalyte is a healthcare technology company that develops and provides diagnostic platforms for rapid, real-time blood testing at the point of care.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotech Equipment, Sensors, Semiconductors
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Genalyte Comparables
Compare Genalyte with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Truvian | 85% | |
| Vital Bio | 81% | |
| Osler Diagnostics | 78% |
For institutional investors. Book with your work email.
Genalyte Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Apr 21, 2023 | ||||
| VC Round | Jan 11, 2021 | ||||
| VC Round | Nov 21, 2016 | ||||
| Series C | Aug 18, 2015 | ||||
| Grant | Aug 20, 2013 | ||||
Grant | Dec 11, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Genalyte Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series C, Series C Extension, VC Round, Series B |
| National Cancer Institute | Grant |
| Khosla Ventures | Series C Extension, VC Round, Series C |
| Provenio Capital | Series C Extension, VC Round |
| Boutique Venture Partners | Series C Extension |
| Invus Opportunities | Series C Extension |
| HBM Healthcare Investments | Series C Extension, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 55% MoM.
- Mar 24, 2026
Merlin platform for diagnostic testing is in development.
For institutional investors. Book with your work email.
Genalyte Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Genalyte's valuation, stock price, and market status.
Is Genalyte a public or private company?
Genalyte is a private company.
What is the current stock price of Genalyte?
Genalyte is a private company, so its shares have no public market price. Caplight tracks Genalyte's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Genalyte worth (valuation)?
Genalyte's valuation is estimated at $302.2M based on funding round data.
Can I buy Genalyte stock?
Genalyte shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Genalyte's last funding round?
Genalyte's most recent funding round was Series C Extension on April 21, 2023.
Who are the main investors in Genalyte?
Key investors in Genalyte include Redmile Group, Khosla Ventures, Boutique Venture Partners.
Will Genalyte IPO soon?
No public IPO plans have been announced for Genalyte.
How can I track Genalyte secondary market activity?
Caplight tracks bids, offers, and trades in Genalyte's shares on secondary markets.